Altimmune, Inc. (ALT) Financials

ALT Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 335.6 million 51.6 million
Dec. 31, 2025 279.9 million 55.0 million
Sept. 30, 2025 218.4 million 32.8 million
June 30, 2025 190.4 million 29.0 million

ALT Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -21.0 million 3.4 million
Dec. 31, 2025 -19.4 million 4.9 million
Sept. 30, 2025 -11.9 million 3.6 million
June 30, 2025 -19.7 million 3.6 million

ALT Net Income

No data available :(

ALT Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 331.5 million 34.5 million 1.3 million
Dec. 31, 2025 273.5 million 34.3 million 1.4 million
Sept. 30, 2025 210.8 million 14.4 million 1.5 million
June 30, 2025 183.1 million 14.3 million 1.5 million

ALT Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 124.5 million
Dec. 31, 2025 100.6 million
Sept. 30, 2025 89.4 million
June 30, 2025 81.5 million

ALT Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 21000 16.2 million 8.1 million -
Dec. 31, 2025 1000 18.4 million 10.5 million -
Sept. 30, 2025 - 15.0 million 5.9 million -
June 30, 2025 10000 17.2 million 5.7 million -

ALT Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 23000
Dec. 31, 2025 26000 26000
Sept. 30, 2025 5000 15.0 million
June 30, 2025 5000 30000

ALT Revenue by Segment
Graph available only for paid members. Upgrade to see it.

ALT

Price: $2.62

52 week price:
2.56
7.73

Payout Ratio Range:
-9112.33%
-2267.61%

Earnings Per Share: -0.92 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 680703

Ebitda: -31.4 million

Market Capitalization: 253.3 million

Links: